This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Penumbra (PEN) Rides on New Product Offerings as FX Woe Ails
by Zacks Equity Research
Penumbra (PEN) sees an acceleration of Lightning Bolt 7 cases as conversion from surgery, lytics and other mechanical thrombectomy products gains momentum.
Bruker (BRKR) Introduces the New Hysitron TI 990 TriboIndenter
by Zacks Equity Research
Bruker's (BRKR) TI 990 is a comprehensive advancement of its industry-leading TriboIndenter platform.
Here's Why You Should Retain Henry Schein (HSIC) Stock for Now
by Zacks Equity Research
Investors are optimistic about Henry Schein (HSIC), backed by the strength of the dental business and acquisitions.
Exact Sciences (EXAS) Aided by Innovation, Strategic Buyouts
by Zacks Equity Research
Exact Sciences (EXAS) is planning several key milestones to bring six innovative cancer diagnostics from its pipeline to patients in need.
Here's Why Investors Should Retain ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about ResMed (RMD) due to the core business' performance and sustained growth in the SaaS business.
Here's Why You Should Retain CVS Health (CVS) Stock for Now
by Zacks Equity Research
Investors continue to remain optimistic about CVS Health (CVS) due to the new acquisitions and the strong execution of the pharmacy business.
Zimmer Biomet (ZBH) Gains From ROSA Sales Growth Amid FX Woes
by Zacks Equity Research
Zimmer Biomet (ZBH) plans to work on the overall shift of the company's legacy knee systems to a fully rounded-out Persona portfolio.
Abbott (ABT) Rides on Nutrition Recovery Amid Low Testing Sales
by Zacks Equity Research
Abbott's (ABT) Nutrition business has started showing signs of recovery since the beginning of 2023.
Quanterix Corporation (QTRX) Moves 7.2% Higher: Will This Strength Last?
by Zacks Equity Research
Quanterix Corporation (QTRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Here's Why You Should Retain Hologic (HOLX) Stock for Now
by Zacks Equity Research
Investors continue to remain optimistic about Hologic (HOLX), backed by the Breast Health business' performance and international execution.
Here's Why Investors Should Retain Labcorp (LH) Stock for Now
by Zacks Equity Research
Investors are increasingly optimistic about Labcorp (LH) due to its progress in hospital partnerships.
Neogen (NEOG) Gains From Strong Segmental Sales, Innovation
by Zacks Equity Research
Within the biosecurity portfolio, Neogen (NEOG) continues to record solid growth in cleaners, disinfectants and rodenticides.
Here's Why Investors Should Retain STERIS (STE) Stock for Now
by Zacks Equity Research
STERIS' (STE) healthcare segment benefits from procedure recovery, boosting investors' optimism.
Here's Why You Should Buy Align Technology (ALGN) Stock Now
by Zacks Equity Research
The rapid expansion of Align Technology's (ALGN) business in international markets remains a key growth driver.
Henry Schein (HSIC) Gains From Strong Global Network Amid FX Woes
by Zacks Equity Research
Henry Schein's (HSIC) dental software business is progressing well despite a challenging business environment.
Terumo's (TRUMY) MicroVention Enters Transradial Access Space
by Zacks Equity Research
The SOFIA EX 5F Catheter by Terumo's (TRUMY) MicroVention boasts a new design to enhance trackability.
Charles River (CRL) Opens a RightSource Lab in Stevenage
by Zacks Equity Research
Charles River's (CRL) new RightSource facility is likely to provide services to the Stevenage advanced therapy biocluster.
ResMed (RMD) Gains From Mask Sales Amid Macro Headwinds
by Zacks Equity Research
ResMed's (RMD) respiratory care business continues to drive growth, courtesy of the adoption of bilevel and other non-invasive ventilator solutions worldwide.
Boston Scientific (BSX) Set to Acquire Relievant Medsystems
by Zacks Equity Research
Boston Scientific's (BSX) new M&A deal is likely to broaden the Neuromodulation business portfolio.
Align (ALGN) Gains From Growing Invisalign Volume, Innovation
by Zacks Equity Research
Align Technology (ALGN) is expanding its sales and marketing by reaching new countries and regions, including new areas within Africa and Latin America.
Medtronic (MDT) Gets CE Mark Approval for the New Simplera CGM
by Zacks Equity Research
Medtronic's (MDT) next-generation sensor Simplera receives CE Mark approval.
Here's Why Investors Should Buy Alcon (ALC) Stock Right Now
by Zacks Equity Research
Investors continue to be optimistic about Alcon (ALC) on the impressive performance of its portfolio.
Abbott (ABT) to Commercialize Biosimilars in Emerging Markets
by Zacks Equity Research
Abbott (ABT) is set to commercialize several biosimilar molecules in key emerging markets via an expanded collaboration with mAbxience.
Orthofix (OFIX) Unveils Gemini System, Advances in Trauma Wing
by Zacks Equity Research
According to Orthofix (OFIX), with the launch of the Galaxy Fixation Gemini system surgeons now have efficient solutions for lower extremity trauma scenarios where time is an important factor.
Hologic (HOLX) Gains From New Launches as Macro Concerns Rise
by Zacks Equity Research
Hologic (HOLX) has been making impressive progress in its Breast Health arm, leveraging its strategic expansion efforts to diversify business across the patient continuum of care.